Introduction
============

Breast cancer is the second most common cancer worldwide, with more than one million new cancer cases annually \[[@b1-crt-2016-259]\]. Breast cancer is also a major cancer in Korea \[[@b2-crt-2016-259]\]. Metastatic breast cancer (MBC) accounts for 20%-30% of all breast cancer cases and remains incurable; therefore, systemic therapy plays an essential role in the treatment of MBC. Among systemic therapies, endocrine therapy (ET) is the mainstay of treatment for patients with hormone receptor (HR)--positive MBC. Because ET is as effective as chemotherapy but less toxic, it should be recommended first in patients with HR-positive MBC except in cases of rapidly progressive disease \[[@b3-crt-2016-259]\].

Aromatase inhibitors (AIs) are commonly used in practice in adjuvant and palliative settings. AIs inhibit the aromatase enzyme, resulting in interruption of estrogen synthesis and suppression of tumor growth \[[@b4-crt-2016-259]-[@b7-crt-2016-259]\]. Currently, there are three clinically available third-generation AIs; two reversible nonsteroidal AIs, letrozole and anastrozole; and one irreversible steroidal AI, exemestane. All three agents are at least as effective as tamoxifen in postmenopausal patients with HR-positive MBC \[[@b4-crt-2016-259]-[@b6-crt-2016-259]\]. A randomized phase III clinical trial to compare letrozole with tamoxifen as first-line treatment showed that letrozole was superior to tamoxifen in terms of objective response rate (ORR), time to progression, and overall survival (OS) \[[@b6-crt-2016-259]\]. However, the majority of trials for AIs were conducted in Western patients. For this reason, there has been no satisfactory clinical data describing letrozole, particularly in Korean patients. Therefore, we investigated the efficacy and toxicity of letrozole as a first-line treatment for postmenopausal patients with HR-positive MBC.

Materials and Methods
=====================

1. Study population
-------------------

We searched all patients who received letrozole as a palliative treatment regardless of ordinal lines of therapy between January 2001 and December 2012 ([Fig. 1](#f1-crt-2016-259){ref-type="fig"}). A total of 407 patients met these criteria. Among the 407 patients, 230 who received prior chemotherapy and 90 treated with a second or further lines of treatment were excluded from our analysis. Menopause was defined as follows: prior bilateral oophorectomy, age \> 60 years, age \< 60 years with amenorrhea for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene, ovarian suppression, or follicle-stimulating hormone/estradiol in the postmenopausal range \[[@b7-crt-2016-259]\]. This protocol was reviewed and approved by the Institutional Review Board of Seoul National University Hospital (SNUH) (IRB No. 1411-038-624). The recommendations of the Declaration of Helsinki were also observed.

2. Data collection
------------------

We reviewed the medical records of all patients for the following characteristics: age, disease status, HR status, human epidermal growth factor receptor 2 (HER-2) status, Ki-67 status, adjuvant treatments, date of recurrence, cancer antigen 15-3 level, number of metastatic organs, and dominant metastatic site. estrogen receptor (ER) or progesterone receptor (PR) positivity was defined as staining for ER or PR ≥ 1% of tumor cells by immunohistochemistry (IHC). HER-2 positivity was defined as an IHC of 3+ or 2+ and HER-2 fluorescence *in situ* hybridization--positive. The high level of Ki-67 was defined as an IHC of Ki-67 ≥ 14% of tumor cells \[[@b8-crt-2016-259]\]. The treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors ver. 1.1. The grading of toxicity was recorded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) ver. 4.0. ET-sensitive was defined as a relapse after ≥ 1 year of completion of adjuvant ET. Disease-free interval (DFI) was calculated from the day of curative resection to the date of tumor recurrence. Progression-free survival (PFS) was measured from the first day of letrozole treatment until tumor progressions or death of any cause. OS was calculated from the first day of letrozole treatment to patient death or the last date of follow-up. ORR was defined as the proportion of patients with either a complete response or a partial response. The clinical benefit rate (CBR) was defined as the proportion of patients achieving the best overall response of complete response, partial response, or stable disease lasting for at least 6 months.

3. Treatment and follow-up
--------------------------

All patients received 2.5 mg letrozole once a day until disease progression or withdrawal due to toxicity or patient's decision. Tumor response was evaluated using the appropriate imaging modalities at least every 2 months in the first 6 months and every 3 months thereafter, or whenever there was clinical evidence of disease progression.

4. Statistical analysis
-----------------------

Categorical variables were compared with the Pearson's chi-square test or Fisher exact test, as appropriate. PFS and OS were calculated using the Kaplan-Meier method. The log-rank test was used to compare the probability of survival between subgroups. Multivariate analysis was performed using the Cox proportional hazards model, and hazard ratios were calculated using a 95% confidence interval. Two-sided p-values of \< 0.05 were considered significant. All analyses were conducted using the PASW ver. 18.0 software package (SPSS Inc., Chicago, IL).

Results
=======

1. Clinicopathological characteristics
--------------------------------------

A total of 84 patients with measurable disease were included in our study. Baseline characteristics of the entire study population are summarized in [Table 1](#t1-crt-2016-259){ref-type="table"}. The mean age at diagnosis of the metastatic or recurrent disease was 59.3±10.5 years (median, 59.3 years; range, 36.4 to 85.7 years). Overall, 54 patients (64.3%) had both ER- and PR-positive tumor, while 27 (32.1%) and three (3.6%) had ER-positive /PR-negative tumor and ER-negative/PR-positive tumor, respectively. Seven patients (8.3%) had HER2-positive breast cancer. Among 46 patients in whom Ki-67 could be determined, 10 (11.9%) had a high level of Ki-67. Moreover, 34 patients (40.5%) had bone-dominant metastasis and 21 patients (25.0%) had lymph node or soft tissue metastasis. Among 48 patients who received adjuvant tamoxifen, 14 (29.2%) had ET-sensitive tumors.

2. Prior treatment
------------------

A total of 74 patients (88.1%) underwent curative surgery. Adjuvant ET data were insufficient for 26 patients; therefore, only 48 (64.9%) received tamoxifen as an adjuvant ET. Moreover, only three patients received anastrozole following tamoxifen as sequential treatment, while 58 (78.4%) received adjuvant chemotherapy. Additionally, 60 patients (81.1%) had a DFI \> 2 years, and 14 patients (29.2%) were ET-sensitive in the adjuvant ET group. The median DFI in ET-sensitive patients was 8.95 years (range, 6.25 to 18.3 years), while the median PFS and median OS were longer in the ET responsive group than the non-responsive group; however, these differences were not statistically significant (median PFS, 12.3 vs. 34.1 months; p=0.266; median OS, 52.6 vs. 74.0 months; p=0.262; log-rank test).

3. The efficacy and survival analysis of letrozole
--------------------------------------------------

The median follow-up was 71 months, and the median duration of treatment was 17.1 months. The most common reasons for discontinuing letrozole were disease progression (97.6%), followed by drug toxicity (arthralgia grade 3, 2.4%). The ORR and CBR were 36.9% and 82.1%, respectively ([Table 2](#t2-crt-2016-259){ref-type="table"}). Median PFS and OS were 16.8 months (95% confidence interval \[CI\], 9.8 to 23.8) and 56.4 months (95% CI, 38.1 to 74.7), respectively ([Fig. 2](#f2-crt-2016-259){ref-type="fig"}). Shorter PFS and OS were seen in patients with a DFI ≤ 2 years or initial metastasis or symptomatic visceral disease ([Fig. 3](#f3-crt-2016-259){ref-type="fig"}).

4. The univariate and multivariate analysis
-------------------------------------------

Subgroup analysis revealed that the ORR for patients with a DFI \> 2 years was significantly higher than that of patients with a DFI ≤ 2 years (43.3% vs. 14.3%, p=0.044) ([Table 3](#t3-crt-2016-259){ref-type="table"}). Univariate analysis revealed that short DFI (≤ 2 years), initial metastasis and symptomatic visceral metastasis were significantly associated with short PFS ([Table 4](#t4-crt-2016-259){ref-type="table"}). However, ET-responsiveness did not affect PFS. Upon multivariate analysis, short DFI (≤ 2 years), initial metastasis and symptomatic visceral metastasis also significantly influenced PFS ([Table 4](#t4-crt-2016-259){ref-type="table"}).

5. Toxicity
-----------

The observed toxicity in our study was limited, with most adverse events being mild to moderate. Only two patients discontinued letrozole due to general weakness and arthralgia. Evaluation of bone health was available for 31 patients. Only one patient (3.2%) had a left proximal humerus fracture related to osteoporosis, while two (6.4%) had newly detected osteoporosis while using letrozole as defined by the NCI-CTCAE ver. 4.0.

Discussion
==========

Upon meta-analysis \[[@b3-crt-2016-259]\], AIs showed similar efficacy and less toxicity than chemotherapy. The phase III trials \[[@b5-crt-2016-259],[@b6-crt-2016-259],[@b9-crt-2016-259]\] demonstrated that anastrozole or letrozole was superior to tamoxifen as a first-line treatment in postmenopausal patients with MBC. Based on both meta-analysis and phase III trials, anastrozole or letrozole is the standard first-line therapy in postmenopausal patients with HR-positive MBC. However, most AI trials in MBC have been tested in Western patients, not Asian patients, and there have not been any data relevant to AIs generated in HR-positive MBC to date, particularly in Korean patients. Moreover, only 40% of Korean patients with breast cancer are postmenopausal \[[@b10-crt-2016-259]\], which seems to be lower than in Western countries. As a result, it is not easy to perform a large-scaled study for AIs, particularly in Korean postmenopausal patients. To the best of our knowledge, even though this is a retrospective analysis, our study has the largest scale of analysis for letrozole as a first-line treatment in Korean postmenopausal patients with HR-positive MBC.

In our study, PFS, OS, and ORR were 16.8 months, 56.4 months, and 36.9%, respectively, which is more favorable than in other studies. Moreover, short DFI and symptomatic visceral metastasis were significantly related to poorer clinical outcomes ([Table 4](#t4-crt-2016-259){ref-type="table"}, [Fig. 3](#f3-crt-2016-259){ref-type="fig"}). Unfortunately, we found no DFI data in phase III trials of and therefore could not compare them with our study directly. It is important to point out that even in the PO25 study \[[@b11-crt-2016-259]\], only the median DFI (5.9 years) was given. In our study, categorization of DFI was based on two years and the median DFI was 6.1 years (range, 0.1 to 37.4 years). Moreover, it is difficult to compare these values directly, because no previous studies divided patients into symptomatic and asymptomatic visceral metastasis. Rather, most studies conducted to date have used nonvisceral and visceral metastases to separate the dominant metastasis. Particularly, in visceral metastasis, only liver involvement was considered, not the symptoms. Therefore, our study is unique in that it confirms symptoms as an important factor.

A randomized phase III (PO25) trial to compare letrozole with tamoxifen in postmenopausal patients with MBC showed better clinical benefits in letrozole \[[@b6-crt-2016-259],[@b11-crt-2016-259]\]. ORR appeared to be similar between our study and the PO25 study. However, PFS and OS in our study were better than in other trials, including the PO25 study. This result may have occurred because the proportion of patients with initial metastasis at diagnosis was much lower than in other phase III studies ([Table 5](#t5-crt-2016-259){ref-type="table"}), and most enrolled subjects were recurrent cases (88.1%) in the present study. The disease burden of recurrent cases may have been smaller at the time of diagnosis since it was detected early through routine regular follow-up examination. The rate of dominant visceral metastasis was greater in the PO25 study (43%) than in our study (34.6%). Moreover, there were fewer patients with relatively adverse dominant metastatic sites such as liver involvement in this study ([Table 5](#t5-crt-2016-259){ref-type="table"}). In addition, one prior chemotherapy regimen for the treatment of metastatic disease was permitted in the PO25 trial, whereas our patients received letrozole treatment as their first-line therapy in the metastatic setting. It is also possible that the patients who were selected to be treated with first-line ET instead of chemotherapy had a tumor with a more indolent nature. Therefore, our results may show better survival than those of previous studies.

Even in the group with visceral metastasis, patients with no symptoms had a median PFS four times longer (40.6 months vs. 8.8 months) and a median OS three times longer (89.5 months vs. 24.2 months) than those with symptoms ([Fig. 3](#f3-crt-2016-259){ref-type="fig"}). Moreover, patients with a DFI ≤ 2 years or initial metastatic diseases also showed shorter survival than those without. Cytotoxic chemotherapy may be preferred for patients of a relatively young age, with short DFI, with initial metastasis or in need of rapid symptom control. Therefore, any of the third generation AIs may be used for front-line treatment of HR-positive MBC in postmenopausal patients without visceral crisis \[[@b12-crt-2016-259],[@b13-crt-2016-259]\]. Treatment decisions are based on symptoms and disease severity (e.g., impending visceral crisis), DFI, patient age, performance status, sites of disease and comorbidities. Other important concerns include patient preferences, maintaining or improving quality of life, and minimizing treatment toxicities. Even if patients had symptoms or metastatic diseases initially, an anti-hormone therapy would be useful when tumor tissues were revealed as strongly ER positive or it is difficult to proceed with chemotherapy because of old age. In our study, although patients had the above risk factors, they were treated with ET if they were elderly, had lower Eastern Cooperative Oncology Group performance scores, or did not want chemotherapy. To date, there has been no evidence of concurrent cytotoxic chemotherapy and cytostatic ET resulting in improved survival among advanced breast cancer patients. Therefore, we recommend ET and chemotherapy be performed sequentially to fit individual patients' situations.

Endocrine resistance is a critical issue for patients with HR-positive MBC. Some tumors harbor intrinsic resistances to endocrine agents, and in the metastatic setting, all tumors ultimately acquire resistance to ET. In this study, there were no statistically significant differences in treatment response and survival between patients who had recurred after ≥ 1 year of completion of adjuvant ET and those who had not. Patients with previous ET (tamoxifen) were included in the Phase III trials shown in [Table 5](#t5-crt-2016-259){ref-type="table"}, and third generation AIs drew favorable clinical outcomes. Moreover, the past tamoxifen treatment history did not affect the AI effect in any of the studies summarized in [Table 5](#t5-crt-2016-259){ref-type="table"}. There are different resistance mechanisms of tamoxifen and letrozole in genome-wide analysis \[[@b14-crt-2016-259]\]; therefore, these findings suggest that there no cross-resistance between these mechanisms. However, the mechanisms underlying resistance to ET are complex \[[@b15-crt-2016-259]\]. Recent studies of PALOMA-1 \[[@b16-crt-2016-259]\], and Turner et al. \[[@b17-crt-2016-259]\] demonstrated that endocrine monotherapy had limited efficacy in patients with disease progression after previous exposure to ET, irrespective of clinically or molecularly defined endocrine sensitivity, suggesting a need for the routine use of more effective combination regimens. In our study, the clinical outcomes with no statistically significant difference according to ET-responsiveness might have occurred because of the relatively small sample sizes. Therefore, further studies and validation are warranted.

It should be noted that our study had the following limitations. First, the retrospective design made it difficult to compare functional status, symptoms, and toxicity profiles among patients. Second, the enrolled patients were selected from a single institution in Korea, and the relatively small sample size may limit the statistical power to derive significant outcomes and correct the differences in subgroup characteristics. Despite these limitations, our analysis investigated a homogeneous patient population with a large case series of postmenopausal women treated with the first line letrozole that were regularly evaluated during and after treatment.

Conclusion
==========

Letrozole showed good efficacy and tolerability in Korean postmenopausal patients. However, the characteristics of Korean patients differ from those of Western patients in terms of age, menopausal status and disease status at first diagnosis. Therefore, a prospective clinical trial to reveal the efficacy and toxicity of AIs in Korean patients is warranted.
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![Progression-free survival (PFS) (A) and overall survival (OS) (B) based on disease-free interval (DFI). Median PFS for initial metastasis, DFI ≤ 2 years and DFI \> 2 years: 9.3 months vs. 11.2 months vs. 22.8 months, p=0.004, log-rank test; median OS: 32.4 months vs. 44.9 months vs. 74.0 months, p=0.001, log-rank test. PFS (C) and OS (D) based on subgroups of dominant metastatic sites. Median PFS for bone, lymph nodes (LNs) or soft tissues, asymptomatic visceral metastasis, and symptomatic visceral metastasis: 18.5 months vs. 17.8 months vs. 40.6 vs. 8.8 months, p=0.002, log-rank test; median OS: 67.8 months vs. 56.4 months vs. 89.5 vs. 24.2 months, p=0.004, log-rank test.](crt-2016-259f3){#f3-crt-2016-259}

###### 

Clinicopathologic characteristics of patients

  Characteristic                                                             No. of patients (%)
  -------------------------------------------------------------------------- ---------------------
  **Total**                                                                  84
   Age, mean (range, yr)                                                     59.3 (36.4-85.7)
    \< 55                                                                    29 (34.5)
    ≥ 55                                                                     55 (65.5)
   Disease status                                                            
    Relapsed disease                                                         74 (88.1)
    Initially metastatic disease                                             10 (11.9)
   Hormonal receptor status^[a)](#tfn1-crt-2016-259){ref-type="table-fn"}^   
    ER+, PR+                                                                 54 (64.3)
    ER+, PR--                                                                27 (32.1)
    ER--, PR+                                                                3 (3.6)
   HER-2 status^[b)](#tfn2-crt-2016-259){ref-type="table-fn"}^               
    Negative                                                                 51 (60.7)
    Positive                                                                 7 (8.3)
    Undetermined                                                             26 (31.0)
   Ki-67 status^[c)](#tfn3-crt-2016-259){ref-type="table-fn"}^               
    Low                                                                      36 (42.9)
    High                                                                     10 (11.9)
    Undetermined                                                             38 (45.2)
  **Prior treatment in relapsed cases (n=74)**                               
   Surgery (n=74)                                                            
    No                                                                       0
    Yes                                                                      74 (100)
   Adjuvant chemotherapy (n=74)                                              
    No                                                                       16 (21.6)
    Yes                                                                      58 (78.4)
    Anthracycline based                                                      27 (36.5)
    Anthracycline+Taxane                                                     9 (12.2)
    CMF                                                                      31 (41.9)
   Adjuvant radiotherapy (n=74)                                              
    No                                                                       50 (67.6)
    Yes                                                                      24 (32.4)
   Adjuvant hormone treatment (n=74)                                         
    Unknown                                                                  26 (35.1)
    Yes                                                                      48 (64.9)
    Tamoxifen alone                                                          45
    Tamoxifen → Anastrozole                                                  3
  **ET-responsiveness (n=48)**                                               
   No                                                                        34 (70.8)
   Sensitive                                                                 14 (29.2)
  **Disease-free interval (yr) (n=74)**                                      
   ≤ 2                                                                       14 (18.9)
   \> 2                                                                      60 (81.1)
  **CA 15-3 level (U/mL) (n=84)**                                            
   ≤ 30                                                                      54 (64.3)
   \> 30                                                                     19 (22.6)
   Unknown                                                                   11 (13.1)
  **Measurable disease (n=84)**                                              
   No                                                                        29 (34.5)
   Yes                                                                       55 (65.5)
  **No. of metastatic organs (n=84)**                                        
   1                                                                         13 (15.5)
   ≥ 2                                                                       71 (84.5)
  **Dominant metastatic site (n=84)**                                        
   Bone                                                                      34 (40.5)
   Lymph node or soft tissue                                                 21 (25.0)
   Asymptomatic visceral metastasis                                          13 (15.5)
   Symptomatic visceral metastasis                                           16 (19.0)

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; CMF, cyclophosphamide+methotrexate+5-fluorouracil; ET, endocrine treatment; CA 15-3, cancer antigen 15-3; IHC, immunohistochemistry.

≥ 1% cells were positive for hormone receptor as assessed by IHC staining,

IHC score 3+ or unequivocal amplification as assessed by fluorescence *in situ* hybridization were positive for HER-2 status,

≥ 14% cells were high for Ki-67 as assessed by IHC.

###### 

The best treatment responses to first-line letrozole

  Best treatment response                                                  No. of patients (%)
  ------------------------------------------------------------------------ ---------------------
  CR+PR                                                                    31 (36.9)
  SD                                                                       47 (56.0)
  PD                                                                       6 (7.1)
  Objective response rate^[a)](#tfn4-crt-2016-259){ref-type="table-fn"}^   31/84 (36.9)
  Clinical benefit rate^[b)](#tfn5-crt-2016-259){ref-type="table-fn"}^     69/84 (82.1)

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

Defined as proportion of patients having the best overall response of either CR or PR,

Defined as the proportion of patients having the best overall response of CR, PR, or SD for at least 6 months.

###### 

Treatment responses in patient subgroups

  Prognostic factor                                                                   Objective response   p-value^[a)](#tfn6-crt-2016-259){ref-type="table-fn"}^   Clinical benefit   p-value^[a)](#tfn6-crt-2016-259){ref-type="table-fn"}^
  ----------------------------------------------------------------------------------- -------------------- -------------------------------------------------------- ------------------ --------------------------------------------------------
  **Age (yr) (n=84)**                                                                                                                                                                  
   \< 55                                                                              8/29 (27.6)          0.199                                                    23/29 (79.3)       0.623
   ≥ 55                                                                               23/55 (41.8)                                                                  46/55 (83.6)       
  **Hormone receptor status^[b)](#tfn7-crt-2016-259){ref-type="table-fn"}^ (n=84)**                                                                                                    
   Both receptors positive                                                            20/54 (37.0)         0.973                                                    44/54 (81.5)       0.832
   Only one receptor positive                                                         11/30 (36.7)                                                                  25/30 (83.3)       
  **HER-2 status^[c)](#tfn8-crt-2016-259){ref-type="table-fn"}^ (n=84)**                                                                                                               
   Negative                                                                           15/51 (29.4)         0.098                                                    42/51 (82.4)       0.720
   Positive                                                                           2/7 (28.6)                                                                    5/7 (71.4)         
   Undetermined                                                                       14/26 (53.8)                                                                  22/26 (84.6)       
  **Ki-67 status^[d)](#tfn9-crt-2016-259){ref-type="table-fn"}^ (n=84)**                                                                                                               
   Low                                                                                10/36 (27.8)         0.194                                                    30/36 (83.3)       0.964
   High                                                                               3/10 (30.0)                                                                   8/10 (80.0)        
   Undetermined                                                                       18/38 (47.4)                                                                  31/38 (81.6)       
  **Disease status (n=74)**                                                                                                                                                            
   Disease-free interval ≤ 2 yr                                                       2/14 (14.3)          0.044                                                    11/14 (78.6)       0.702
   Disease-free interval \> 2 yr                                                      26/60 (43.3)                                                                  50/60 (83.3)       
  **No. of metastatic organs (n=84)**                                                                                                                                                  
   1                                                                                  3/13 (23.1)          0.355                                                    11/13 (84.6)       1.000
   ≥ 2                                                                                28/71 (39.4)                                                                  58/71 (81.7)       
  **Dominant metastatic site (n=84)**                                                                                                                                                  
   Bone                                                                               9/34 (26.5)          0.217                                                    29/34 (85.3)       0.136
   Lymph node or soft tissue                                                          11/21 (52.4)                                                                  18/21 (85.7)       
   Asymptomatic visceral metastasis                                                   6/13 (46.2)                                                                   12/13 (92.3)       
   Symptomatic visceral metastasis                                                    5/16 (31.3)                                                                   10/16 (62.5)       
  **ET-responsiveness (n=48)**                                                                                                                                                         
   No                                                                                 11/34 (32.4)         0.251                                                    27/34 (79.4)       0.407
   Sensitive                                                                          7/14 (50.0)                                                                   13/14 (92.9)       

Values are presented as number (%). HER-2, human epidermal growth factor receptor 2; ET, endocrine treatment; IHC, immunohistochemistry.

Chi-square test,

≥ 1% cells were positive for hormone receptors as assessed by IHC staining,

IHC score 3+ or unequivocal amplification as assessed by fluorescence *in situ* hybridization were positive for HER-2 status,

≥ 14% cells were high for Ki-67 as assessed by IHC.

###### 

Univariate and multivariate analyses of predictive factors for progression-free survival

  Prognostic factor                                                                    Univariate            Multivariate                         
  ------------------------------------------------------------------------------------ --------------------- -------------- --------------------- -------
  **Age (yr) (n=84)**                                                                                                                             
   \< 55                                                                               1                     0.782          1                     0.793
   ≥ 55                                                                                1.073 (0.652-1.765)                  1.085 (0.590-1.998)   
  **Hormone receptor status^[b)](#tfn11-crt-2016-259){ref-type="table-fn"}^ (n=84)**                                                              
   Both receptors positive                                                             1                     0.798          1                     0.375
   One receptor positive only                                                          1.067 (0.649-1.753)                  1.285 (0.738-2.240)   
  **HER-2 status^[c)](#tfn12-crt-2016-259){ref-type="table-fn"}^ (n=84)**                                                                         
   Negative                                                                            1                     0.291          1                     0.642
   Positive                                                                            1.134 (0.664-1.936)   0.644          0.709 (0.279-1.804)   0.471
   Undetermined                                                                        1.977 (0.829-4.716)   0.124          0.790 (0.437-1.426)   0.434
  **Ki-67 status^[d)](#tfn13-crt-2016-259){ref-type="table-fn"}^ (n=84)**                                                                         
   Low                                                                                 1                     0.401          1                     0.341
   High                                                                                1.474 (0.709-3.065)   0.299          1.964 (0.735-5.247)   0.178
   Undetermined                                                                        0.903 (0.540-1.512)   0.699          1.457 (0.784-2.708)   0.234
  **Disease status (n=84)**                                                                                                                       
   Disease-free interval \> 2 yr                                                       1                     0.004          1                     0.009
   Disease-free interval ≤ 2 yr                                                        2.051 (1.095-3.840)   0.025          2.697 (1.262-5.762)   0.010
   Initially metastatic disease                                                        2.907 (1.376-6.140)   0.005          2.519 (1.113-5.703)   0.027
  **No. of metastatic organs (n=84)**                                                                                                             
   1                                                                                   1                     0.174          1                     0.230
   ≥ 2                                                                                 1.675 (0.797-3.523)                  1.635 (0.733-3.646)   
  **Dominant metastatic site (n=84)**                                                                                                             
   Bone                                                                                1                     0.002          1                     0.004
   Lymph node or soft tissue                                                           1.380 (0.756-2.519)   0.294          1.122 (0.552-2.282)   0.750
   Asymptomatic visceral metastasis                                                    0.813 (0.389-1.696)   0.581          0.721 (0.331-1.572)   0.411
   Symptomatic visceral metastasis                                                     3.077 (1.584-5.975)   0.001          3.437 (1.576-7.495)   0.002
  **ET-responsiveness (n=48)**                                                                                                                    
   No                                                                                  1                     0.252          1                     0.455
   Sensitive                                                                           0.680 (0.351-1.317)                  0.749 (0.352-1.597)   

HR, hazard ratio; CI, confidence interval; HER-2, human epidermal growth factor receptor 2; ET, endocrine treatment; IHC, immunohistochemistry.

Cox proportional hazard model,

≥ 1% cells were positive for hormone receptor as assessed by IHC staining,

IHC score 3+ or unequivocal amplification as assessed by fluorescence *in situ* hybridization were positive for HER-2 status,

≥ 14% cells were high for Ki-67 as assessed by IHC.

###### 

Phase III trials using AIs as first-line treatment in postmenopausal patients with MBC

                                                            Bonneterre et al. \[[@b5-crt-2016-259]\]                      Nabholtz et al. \[[@b9-crt-2016-259]\]   Mouridsen et al. \[[@b6-crt-2016-259], [@b18-crt-2016-259]\]               Our study
  --------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------- -------------------------------------------------------------------------- ------------------------
  **Design**                                                Phase III                                                     Phase III                                Phase III                                                                  Retrospective analysis
  **Population**                                            Europe, Australia, New Zealand, South America, South Africa   USA, Canada                              Europe, North America, South America, South Africa, India, Egypt, Israel   Korea
  **Investigating agent**                                   Anastrozole (n=340)                                           Anastrozole (n=171)                      Letrozole (n=453)                                                          Letrozole (n=84)
  **Age, mean (range, yr)**                                 67 (34-91)                                                    68                                       65 (31-96)                                                                 59 (36-86)
  **Disease status at first diagnosis**                                                                                                                                                                                                       
   Initial metastasis (%)                                   48                                                            30                                       32                                                                         12
   Relapse (%)                                              52                                                            69                                       68                                                                         88
  **Overall response rate (%)**                             32.9                                                          21                                       32                                                                         37
  **Median time to progression (mo)**                       8.2                                                           11.1                                     9.4                                                                        16.8
  **Nonvisceral metastasis, n (%)**                         237 (69.7)                                                    88 (51.5)                                258 (57)                                                                   55 (65.5)
   Median TTP (mo)                                          \-                                                            \-                                       10.9                                                                       18.1
  **Viscera metastasis without liver involvement, n (%)**   71 (20.9)                                                     70 (40.9)                                135 (29.8)                                                                 26 (31)
   Median TTP (mo)                                          \-                                                            \-                                       11.9                                                                       16.8
  **Viscera metastasis with liver involvement, n (%)**      32 (9.4)                                                      13 (7.6)                                 60 (13.2)                                                                  3 (3.6)
   Median TTP (mo)                                          \-                                                            \-                                       3.8                                                                        10.0

AI, aromatase inhibitor; MBC, metastatic breast cancer.

[^1]: Seung Hoon Beom and Jisu Oh contributed equally to this work.
